Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

New oral anticoagulants (OACs) that directly inhibit Factor Xa (FXa) or thrombin have been
developed for the long-term prevention of thromboembolic disorders. These novel agents …

Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information
is available on the reversal of the antihemostatic action of apixaban in experimental or …

New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of
stroke in patients with non-valvular atrial fibrillation. Two agents are direct factor Xa …

Objective Apixaban is a substrate of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein.
The effects of rifampin, a strong inducer of CYP3A4 and P-glycoprotein, on the …

Abstract The direct factor Xa (FXa) inhibitors rivaroxaban, apixaban and edoxaban, and the
thrombin inhibitor dabigatran etexilate (dabigatran) have gained approval for use in several …

Background Novel oral anticoagulants are approved in several indications: rivaroxaban,
apixaban, and dabigatran for the prevention of venous thromboembolism after elective hip …

Objectives To systematically review available evidence and establish guidelines related to
the risk of developing thrombosis and the management of small animals with …

Four target-specific oral anticoagulants (TSOA's) have been compared to a vitamin K
antagonist for the treatment of acute venous thromboembolism (VTE): dabigatran (D) …